Shenglei Shu1,2, Ziming Hong3, Qinmu Peng3, Xiaoyue Zhou4, Tianjng Zhang5, Jing Wang1,2, Chuansheng Zheng1,2. 1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China. 3. School of Electronic Information and Communications, Huazhong University of Science and Technology, Wuhan, China. 4. MR Collaboration, Siemens Healthineers, Shanghai, China. 5. Philips Healthcare, Guangzhou, China.
Abstract
OBJECTIVE: Patients with dilated cardiomyopathy (DCM) and severely reduced left ventricular ejection fractions (LVEFs) are at very high risks of experiencing adverse cardiac events. A machine learning (ML) method could enable more effective risk stratification for these high-risk patients by incorporating various types of data. The aim of this study was to build an ML model to predict adverse events including all-cause deaths and heart transplantation in DCM patients with severely impaired LV systolic function. METHODS: One hundred and eighteen patients with DCM and severely reduced LVEFs (<35%) were included. The baseline clinical characteristics, laboratory data, electrocardiographic, and cardiac magnetic resonance (CMR) features were collected. Various feature selection processes and classifiers were performed to select an ML model with the best performance. The predictive performance of tested ML models was evaluated using the area under the curve (AUC) of the receiver operating characteristic curve using 10-fold cross-validation. RESULTS: Twelve patients died, and 17 patients underwent heart transplantation during the median follow-up of 508 days. The ML model included systolic blood pressure, left ventricular end-systolic and end-diastolic volume indices, and late gadolinium enhancement (LGE) extents on CMR imaging, and a support vector machine was selected as a classifier. The model showed excellent performance in predicting adverse events in DCM patients with severely reduced LVEF (the AUC and accuracy values were 0.873 and 0.763, respectively). CONCLUSIONS: This ML technique could effectively predict adverse events in DCM patients with severely reduced LVEF. ADVANCES IN KNOWLEDGE: The ML method has superior ability in risk stratification in severe DCM patients.
OBJECTIVE: Patients with dilated cardiomyopathy (DCM) and severely reduced left ventricular ejection fractions (LVEFs) are at very high risks of experiencing adverse cardiac events. A machine learning (ML) method could enable more effective risk stratification for these high-risk patients by incorporating various types of data. The aim of this study was to build an ML model to predict adverse events including all-cause deaths and heart transplantation in DCM patients with severely impaired LV systolic function. METHODS: One hundred and eighteen patients with DCM and severely reduced LVEFs (<35%) were included. The baseline clinical characteristics, laboratory data, electrocardiographic, and cardiac magnetic resonance (CMR) features were collected. Various feature selection processes and classifiers were performed to select an ML model with the best performance. The predictive performance of tested ML models was evaluated using the area under the curve (AUC) of the receiver operating characteristic curve using 10-fold cross-validation. RESULTS: Twelve patients died, and 17 patients underwent heart transplantation during the median follow-up of 508 days. The ML model included systolic blood pressure, left ventricular end-systolic and end-diastolic volume indices, and late gadolinium enhancement (LGE) extents on CMR imaging, and a support vector machine was selected as a classifier. The model showed excellent performance in predicting adverse events in DCM patients with severely reduced LVEF (the AUC and accuracy values were 0.873 and 0.763, respectively). CONCLUSIONS: This ML technique could effectively predict adverse events in DCM patients with severely reduced LVEF. ADVANCES IN KNOWLEDGE: The ML method has superior ability in risk stratification in severe DCM patients.
Authors: Damini Dey; Piotr J Slomka; Paul Leeson; Dorin Comaniciu; Sirish Shrestha; Partho P Sengupta; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2019-03-26 Impact factor: 24.094
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: Circulation Date: 2017-04-28 Impact factor: 29.690
Authors: Marthe A J Becker; Jan H Cornel; Peter M van de Ven; Albert C van Rossum; Cornelis P Allaart; Tjeerd Germans Journal: JACC Cardiovasc Imaging Date: 2018-04-18
Authors: Leah M Iles; Andris H Ellims; Huw Llewellyn; James L Hare; David M Kaye; Catriona A McLean; Andrew J Taylor Journal: Eur Heart J Cardiovasc Imaging Date: 2014-10-28 Impact factor: 6.875
Authors: Wenya Linda Bi; Ahmed Hosny; Matthew B Schabath; Maryellen L Giger; Nicolai J Birkbak; Alireza Mehrtash; Tavis Allison; Omar Arnaout; Christopher Abbosh; Ian F Dunn; Raymond H Mak; Rulla M Tamimi; Clare M Tempany; Charles Swanton; Udo Hoffmann; Lawrence H Schwartz; Robert J Gillies; Raymond Y Huang; Hugo J W L Aerts Journal: CA Cancer J Clin Date: 2019-02-05 Impact factor: 508.702
Authors: Heinz-Peter Schultheiss; DeLisa Fairweather; Alida L P Caforio; Felicitas Escher; Ray E Hershberger; Steven E Lipshultz; Peter P Liu; Akira Matsumori; Andrea Mazzanti; John McMurray; Silvia G Priori Journal: Nat Rev Dis Primers Date: 2019-05-09 Impact factor: 65.038